A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis. (1st November 2016)

• Record Type: Journal Article
• Authors: Tsai, Her Hsin; Black, Christopher
• Is Part Of: Expert review of pharmacoeconomics & outcomes research. Volume 16:Number 6(2016)
• Page Start: 679
• Page End: 683
• Publication Date: 2016-11-01
• Subjects: Vedolizumab -- cost-effectiveness -- ulcerative colitis -- inflammatory bowel disease; Pharmacology -- Economic aspects -- Periodicals; 338.47615105
• DOI: 10.1080/14737167.2016.1246186
• Languages: English
• ISSNs: 1473-7167

Abstract

ABSTRACT: Introduction : Vedolizumab is a novel humanised monoclonal IgG1 antibody gut selective anti-integrin specifically targeting α4β7 integrins in the gut and found to be efficacious in the treatment of ulcerative colitis. Areas covered : Research investigating the cost-effectiveness of vedolizumab is limited. This review considers data from the manufacturers, the evidence research group commissioned by NICE to conduct a single technology appraisal, and the decision of NICE itself to appraise what is currently known about the cost-effectiveness of vedolizumab for moderately to severely active ulcerative from a UK perspective. Expert commentary : Based on the very limited data currently available, it can be concluded that vedolizumab is a cost-effective option for those with moderately to severely active ulcerative colitis who are anti-TNFa naive; however, there is a need for further research comparing vedolizumab with other biologic therapies which may alter perceptions of cost-effectiveness.